GenOway establishes a presence in Japan with a new subsidiary

genOway, a French company specializing in preclinical solutions, announces the opening of its subsidiary, genOway Japan. This is part of its international expansion strategy aimed at penetrating the Japanese market, the third largest in the world for preclinical research. The company expects to generate between 5 and 10 million euros in revenue from this initiative.

Led by Dr. Hideki Hanaoka, who has over 20 years of experience in life sciences in Japan, the new subsidiary is based on a proven model from China. Philippe Fauchet, an expert in the Japanese biopharmaceutical ecosystem, will chair the Board of Directors. Sales are expected to begin in the second half of 2026.